Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Bio-Path Holdings ( (BPTH) ) has issued an announcement.
Bio-Path Holdings announced significant advancements in its clinical development pipeline for 2025, including the exploration of its lead product, prexigebersen, in treating both acute myeloid leukemia (AML) and obesity in Type 2 Diabetes patients. The company is focusing on utilizing molecular biomarkers to enhance patient response rates in its Phase 2 AML trial and is preparing to file an Investigational New Drug application for BP1001-A’s obesity treatment. Concurrently, Bio-Path is progressing with Phase 1/1b trials for BP1001-A and BP1002, aiming to address unmet needs in solid tumors and venetoclax-resistant AML. These developments are poised to potentially improve patient outcomes and expand Bio-Path’s market reach in oncology and metabolic disorder treatments.
More about Bio-Path Holdings
Bio-Path Holdings, Inc. is a biotechnology company specializing in the development of nucleic acid cancer and obesity drugs using its proprietary DNAbilize® liposomal delivery and antisense technology. The company focuses on creating targeted treatments for cancer and obesity-related conditions, including Type 2 Diabetes, through a pipeline of RNAi nanoparticle drugs.
YTD Price Performance: -14.96%
Average Trading Volume: 2,119,436
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.21M
For an in-depth examination of BPTH stock, go to TipRanks’ Stock Analysis page.
